NO125182B - - Google Patents
Download PDFInfo
- Publication number
- NO125182B NO125182B NO4991/68A NO499168A NO125182B NO 125182 B NO125182 B NO 125182B NO 4991/68 A NO4991/68 A NO 4991/68A NO 499168 A NO499168 A NO 499168A NO 125182 B NO125182 B NO 125182B
- Authority
- NO
- Norway
- Prior art keywords
- carboxylic acid
- gave
- nonane
- melting point
- acid
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 13
- -1 5-cyanobicyclo-[3.2.2]-nonane-1-carboxylic acid Chemical compound 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 4
- ONXKUOTWYIGFMY-UHFFFAOYSA-N 1-cyanobicyclo[2.2.2]octane-4-carboxylic acid Chemical compound C1CC2(C#N)CCC1(C(=O)O)CC2 ONXKUOTWYIGFMY-UHFFFAOYSA-N 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 24
- 238000002844 melting Methods 0.000 description 23
- 230000008018 melting Effects 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 21
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 239000000463 material Substances 0.000 description 18
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- 238000001953 recrystallisation Methods 0.000 description 16
- 239000000203 mixture Substances 0.000 description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000004809 thin layer chromatography Methods 0.000 description 9
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 7
- 229960002684 aminocaproic acid Drugs 0.000 description 7
- 239000000538 analytical sample Substances 0.000 description 7
- 238000004821 distillation Methods 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 6
- 108010088842 Fibrinolysin Proteins 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 6
- 235000019341 magnesium sulphate Nutrition 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 102000013566 Plasminogen Human genes 0.000 description 5
- 108010051456 Plasminogen Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003776 cleavage reaction Methods 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000003480 eluent Substances 0.000 description 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 5
- 230000003480 fibrinolytic effect Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 239000003527 fibrinolytic agent Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
- 229940012957 plasmin Drugs 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- GYDJEQRTZSCIOI-UHFFFAOYSA-N Tranexamic acid Chemical compound NCC1CCC(C(O)=O)CC1 GYDJEQRTZSCIOI-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 239000000504 antifibrinolytic agent Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- PSLIMVZEAPALCD-UHFFFAOYSA-N ethanol;ethoxyethane Chemical compound CCO.CCOCC PSLIMVZEAPALCD-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- MUMZUERVLWJKNR-UHFFFAOYSA-N oxoplatinum Chemical compound [Pt]=O MUMZUERVLWJKNR-UHFFFAOYSA-N 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 229910003446 platinum oxide Inorganic materials 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- VEFLKXRACNJHOV-UHFFFAOYSA-N 1,3-dibromopropane Chemical compound BrCCCBr VEFLKXRACNJHOV-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- 102000009123 Fibrin Human genes 0.000 description 2
- 108010073385 Fibrin Proteins 0.000 description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 2
- 229910000564 Raney nickel Inorganic materials 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- QCTBMLYLENLHLA-UHFFFAOYSA-N aminomethylbenzoic acid Chemical compound NCC1=CC=C(C(O)=O)C=C1 QCTBMLYLENLHLA-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000010531 catalytic reduction reaction Methods 0.000 description 2
- 150000005690 diesters Chemical class 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 2
- 229950003499 fibrin Drugs 0.000 description 2
- 238000005984 hydrogenation reaction Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 1
- VYMPLPIFKRHAAC-UHFFFAOYSA-N 1,2-ethanedithiol Chemical compound SCCS VYMPLPIFKRHAAC-UHFFFAOYSA-N 0.000 description 1
- JKYSFPLAGCMMOI-UHFFFAOYSA-N 2,4-dichloro-7-(trifluoromethoxy)quinazoline Chemical compound ClC1=NC(Cl)=NC2=CC(OC(F)(F)F)=CC=C21 JKYSFPLAGCMMOI-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- GCRVQZOJASYKQO-UHFFFAOYSA-N 5-ethoxycarbonylbicyclo[3.2.2]nonane-1-carboxylic acid Chemical compound C1CC2(C(O)=O)CCC1(C(=O)OCC)CCC2 GCRVQZOJASYKQO-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 238000003512 Claisen condensation reaction Methods 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960003375 aminomethylbenzoic acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 230000001567 anti-fibrinolytic effect Effects 0.000 description 1
- 229940082620 antifibrinolytics Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WXAXNYYAYJKARR-UHFFFAOYSA-N benzene;2-(1,4-dioxan-2-yl)acetic acid Chemical compound C1=CC=CC=C1.OC(=O)CC1COCCO1 WXAXNYYAYJKARR-UHFFFAOYSA-N 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- RBHJBMIOOPYDBQ-UHFFFAOYSA-N carbon dioxide;propan-2-one Chemical compound O=C=O.CC(C)=O RBHJBMIOOPYDBQ-UHFFFAOYSA-N 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000002612 cardiopulmonary effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- SKCNIGRBPJIUBQ-UHFFFAOYSA-N chloroform;ethyl acetate Chemical compound ClC(Cl)Cl.CCOC(C)=O SKCNIGRBPJIUBQ-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- BNHRUAKQHCIHOS-UHFFFAOYSA-N diethyl 7,9-dioxobicyclo[3.2.2]nonane-1,5-dicarboxylate Chemical compound C1C(=O)C2(C(=O)OCC)CC(=O)C1(C(=O)OCC)CCC2 BNHRUAKQHCIHOS-UHFFFAOYSA-N 0.000 description 1
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940001501 fibrinolysin Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000003822 preparative gas chromatography Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007127 saponification reaction Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Analogifremgangsmåte ved fremstilling av terapeutisk aktive, bicyclo-£2 . 2 . 2~ -octan- og - L3 . 2.2J -nonan-l-carboxylsyrederivater . Analogy method in the preparation of therapeutically active, bicyclo-£2 . 2. 2~ -octane- and - L3 . 2.2J -Nonane-1-carboxylic acid derivatives.
Foreliggende oppfinnelse angår en fremgangsmåte ved fremstilling av nye ant i-fibrinolytiske forbindelser som er egnet for å mot-virke visse blødningstilstander og andre lidelser som skyldes en patologisk fibrinolytisk tilstand hos pasientene. De nye forbindelser som fremstilles ifølge oppfinnelsen, har formelen: The present invention relates to a method for the production of new anti-fibrinolytic compounds which are suitable for counteracting certain bleeding conditions and other disorders caused by a pathological fibrinolytic condition in patients. The new compounds produced according to the invention have the formula:
hvor n er 2 eller 3, og X'ene, som er like, er enten H2 eller O. For å forhindre eller behandle en patologisk fibrinolytisk tilstand where n is 2 or 3, and the X's, which are equal, are either H2 or O. To prevent or treat a pathological fibrinolytic condition
hos pasienter anvendes ved oral administrasjon fra 1 til 20, og for-trinnsvis 2 til 8 mg/kg legemsvekt pr. dag av fremgangsmåteforbindelsene i varierende behandlingstidsrom. in patients is used by oral administration from 1 to 20, and preferably 2 to 8 mg/kg body weight per day of the procedure compounds in varying treatment time slots.
Oppløsningen av fibrinavleiringer i pattedyr skyldes deres lyse av enzymet plasmin (fibrinolysin) som dannes i blodet fra plasminogen, som også er tilstede i blodet. Denne overføring fra plasminogen til plasmin fremmes av aktivatorer i blodet, og det synes at for stor fibrinolytisk aktivitet skyldes en for rikelig tilstedeværelse av slike aktivatorer. Når for meget plasmin er tilstede, blir blodets klumpningssystem ubalansert, voksbare klumper kan ikke opprettholdes og blødning kan følge. Denne situasjon er kjent som en fibrinolytisk tilstand. Andre enzymsystemer (dvs. kallikreinene, komplement) kan også aktiveres på uønsket vis når en slik tilstand foreligger. The dissolution of fibrin deposits in mammals is due to their lysis by the enzyme plasmin (fibrinolysin) which is formed in the blood from plasminogen, which is also present in the blood. This transfer from plasminogen to plasmin is promoted by activators in the blood, and it seems that excessive fibrinolytic activity is due to an excessive presence of such activators. When too much plasmin is present, the blood's clotting system becomes unbalanced, waxy clots cannot be maintained and bleeding can ensue. This situation is known as a fibrinolytic state. Other enzyme systems (ie the kallikreins, complement) can also be activated in an unwanted way when such a condition exists.
Der har nylig utviklet seg en interesse for anti-fibrinolytiske midler, dvs. droger som vil inhibere aktiveringen av plasminogen til å danne plasmin. Disse anti-fibrinolytiske midler antaes å gripe forstyrrende inn i funksjonen av aktivatorene som overfører plasminogen til plasmin. Den kliniske anvendelse av slike droger innbefatter administreringen av dem til personer som under-kastes forskjellige slags kirurgi (som hjerte-lunge- og prostata-kirurgi), obstetriske blødningsproblemer, menorrhagia, og mange andre anvendelser som har vært foreslått i litteraturen (se f.eks. Nilssen, Acta Medica Scand. Suppl. 448, bind l8o, 1966). There has recently developed an interest in anti-fibrinolytic agents, i.e. drugs that will inhibit the activation of plasminogen to form plasmin. These anti-fibrinolytic agents are believed to interfere with the function of the activators that transfer plasminogen to plasmin. The clinical use of such drugs includes their administration to subjects undergoing various types of surgery (such as cardiopulmonary and prostate surgery), obstetric bleeding problems, menorrhagia, and many other uses that have been suggested in the literature (see e.g. eg Nilssen, Acta Medica Scand. Suppl. 448, vol. l8o, 1966).
Et standard anti-fibrinolytisk middel mot hvilket nyere midler i alminnelighet prøves og sammenlignes, er epsilon-amino-capronsyre, kjent som EACA. En mangel ved dette middel har vært de meget høye doser som trenges, i noen tilfelle 3 - 6 g eller mere, hver 4- til 6. time. Dessuten har bivirkninger som svimmelhet, kvalme og diaré være iakttatt. Nylig har to sterkere midler vært beskrevet, nemlig trans-4-aminomethylcyclohexancarboxylsyre (AMCHA) og 4-amino-methylbenzoesyre (PAMBA). Begge har vært angitt å være mere aktiv enn EACA såvel ved in vitro som in vivo prøver (se f.eks. Anderssen et al. Scand. J. Haemat . (1965) 2_, 230 og Melander et al Acta Pharmacol. et Toxicol 1965 22, 340, som begge angår AMCHA). A standard anti-fibrinolytic agent against which newer agents are generally tried and compared is epsilon-amino-caproic acid, known as EACA. A shortcoming of this agent has been the very high doses required, in some cases 3 - 6 g or more, every 4 to 6 hours. In addition, side effects such as dizziness, nausea and diarrhea have been observed. Recently, two more potent agents have been described, namely trans-4-aminomethylcyclohexanecarboxylic acid (AMCHA) and 4-amino-methylbenzoic acid (PAMBA). Both have been indicated to be more active than EACA in both in vitro and in vivo tests (see e.g. Anderssen et al. Scand. J. Haemat. (1965) 2_, 230 and Melander et al. Acta Pharmacol. et Toxicol 1965 22, 340, both of which concern AMCHA).
Forbindelser ble undersøkt in vitro ved å måle virkningen av inhibitoren ved forskjellige konsentrasjoner på lysetidene av en fibrinklump med en konstant konsentrasjon av streptokinase i plas-minogenrik plasma. Den konsentrasjon av inhibitoren som øker den geometriske middellysetid med 50% ble beregnet. Epsilon-amino-capronsyre (EACA). ble anvendt som standard og de relative styrker ble erholdt med følgende resultater: Compounds were examined in vitro by measuring the effect of the inhibitor at various concentrations on the light times of a fibrin clot with a constant concentration of streptokinase in plasminogen-rich plasma. The concentration of the inhibitor that increases the geometric mean light time by 50% was calculated. Epsilon-amino-caproic acid (EACA). was used as a standard and the relative strengths were obtained with the following results:
Det fremgår av disse resultater at fremgangsmåteforbindelsene oppviser aktiviteter på 15 til lOO ganger den for EACA på molar-basis, i prøver som er kjent for å stemme med kliniske resultater. Dette gjør det. mulig å anvende meget mindre doser av drogen ved behandling av patologiske fibrinolytiske tilstander. It appears from these results that the process compounds exhibit activities of 15 to 100 times that of EACA on a molar basis, in samples known to agree with clinical results. This does it. possible to use much smaller doses of the drug in the treatment of pathological fibrinolytic conditions.
De nye fremgangsmåteforbindelser har den generelle formel: The new process compounds have the general formula:
hvor n er 2 eller 3> og X'ene, som er like, er eller O. De er således 4~aininomethylbicyclo-[2 .2 .2 ] -oetan-1 -carboxylsyre , 5-aminomethylbicyclo-[3.2.2j-nonan-1-carboxylsyre og de tilsvarende diketo-forbindelser. Videre modifikasjon av denne molekylanordning, som substitusjon på nitrogenatomet eller fjernelse av -CH2~ mellom nitrogenatomet og ringen, synes å ødelegge aktiviteten. where n is 2 or 3> and the X's, which are the same, are or O. They are thus 4~aininomethylbicyclo-[2 .2 .2 ]-oethane-1-carboxylic acid , 5-aminomethylbicyclo-[3.2.2j- nonane-1-carboxylic acid and the corresponding diketo compounds. Further modification of this molecular arrangement, such as substitution on the nitrogen atom or removal of -CH2~ between the nitrogen atom and the ring, seems to destroy the activity.
Særlig foretrukket er forbindelsen 4-aminomethylbicyclo-[2.2.2j-octan-l-carboxylsyre, som viser minst 50 ganger aktiviteten av EACA in vitro og er 8 ganger så aktiv in vivo i hunder. Denne forbindelse har den ytterligere fordel at den absorberes ved oral administrasjon, nesten så godt som når den gies intravenøst. Particularly preferred is the compound 4-aminomethylbicyclo-[2.2.2j-octane-1-carboxylic acid, which shows at least 50 times the activity of EACA in vitro and is 8 times as active in vivo in dogs. This compound has the additional advantage of being absorbed by oral administration almost as well as when given intravenously.
Fremgangsmåteforbindelsene fremstilles ved katalytisk reduksjon av den tilsvarende 4-cyanobicyclo-octan- eller nonan-l-carboxylsyre. I tilfelle av bicyclooctansyre er cyanoforbindelsen kjent (Roberts et al. J. Am. Chem. Soc. 7J5, 637 (1953))- Den tilsvarende bicyclononan-cyanosyre fremstilles av en lignende syntetisk vei ved hvilken 1,3-dibrompropan anvendes istedenfor 1,2-dibromethan i det annet trinn. Disse synteser er beskrevet i prosesskjemaet. Keto-forbindelsene fremstilles på lignende måte unntatt at ketogruppene beskyttes inntil til slutt som ethylenketalderivater. The process compounds are prepared by catalytic reduction of the corresponding 4-cyanobicyclo-octanoic or nonane-1-carboxylic acid. In the case of bicyclooctanoic acid, the cyano compound is known (Roberts et al. J. Am. Chem. Soc. 7J5, 637 (1953))- The corresponding bicyclononane-cyanoacid is prepared by a similar synthetic route in which 1,3-dibromopropane is used instead of 1, 2-dibromoethane in the second step. These syntheses are described in the process diagram. The keto compounds are prepared in a similar manner except that the keto groups are protected until the end as ethylene ketal derivatives.
Definisjoner R = ethyl, og n = 2 eller 3. Definitions R = ethyl, and n = 2 or 3.
Reaksjoner Reactions
(1) Claisen-kondensasjon med NaOC^H^. (1) Claisen condensation with NaOC^H^.
(2) Omsetning med NaH eller annen sterk base fulgt av (2) Reaction with NaH or other strong base followed by
Br(CH2)n<Br.>Br(CH2)n<Br.>
(3) Omsetning med HS-(CH2)2"SH i nærvær av BF^-etherat i is-eddik. (3) Reaction with HS-(CH2)2"SH in the presence of BF^ etherate in glacial acetic acid.
(4) Reduksjon med Raney-nikkel. (4) Reduction with Raney nickel.
(5) Forsiktig forsåpning med en base som NaOH i vandig alkohol. (6) Omsetning med triethylamin og klormaursyreester, fulgt av ammoniakk for å overføre anhydridet til amidet. (7) Dehydratisering med POCl^ i 1,2-diklorethan eller pyridin. (5) Careful saponification with a base such as NaOH in aqueous alcohol. (6) Reaction with triethylamine and chloroformate, followed by ammonia to transfer the anhydride to the amide. (7) Dehydration with POCl^ in 1,2-dichloroethane or pyridine.
(8) Oppvarmning med base som NaOH i vandig alkohol. (8) Heating with a base such as NaOH in aqueous alcohol.
(9) Katalytisk reduksjon, som over Pt i vandig alkoholisk HCl-oppløsning. (10) Omsetning med 1 ,2-ethylenglycol i nærvær av toluensulfon-syre i benzen. (9) Catalytic reduction, as over Pt in aqueous alcoholic HCl solution. (10) Reaction with 1,2-ethylene glycol in the presence of toluenesulfonic acid in benzene.
(11) Oppvarmning med syre. (11) Heating with acid.
Fremgangsmåteforbindelsene anvendes ved enten oral eller intra-venøs administrasjon, skjønt den orale vei foretrekkes. Esterne og amidene av denne gruppe forbindelser er ikke selv meget aktive in vitro, men virkningen av enzymer in vivo kan bevirke den langsomme frigjørelse av de meget aktive aminosyrer og således skaffe en for-lenget tilgjengelighet av drogen i legemet. Dette er viktig på grunn av tilbøyeligheten hos disse droger til hurtig å elimineres i urinen . The method compounds are used by either oral or intravenous administration, although the oral route is preferred. The esters and amides of this group of compounds are not themselves very active in vitro, but the action of enzymes in vivo can cause the slow release of the very active amino acids and thus provide a prolonged availability of the drug in the body. This is important because of the tendency of these drugs to be quickly eliminated in the urine.
Fremgangsmåteforbindelsene kan anvendes i en hvilken som helst farmasøytisk godtagbar bærer, i form av piller, tabletter eller kapsler. De farmasøytisk godtagbare salter (både av aminogruppen, som hydrokloridet, hydrobromidet, sulfatet, citratet, tartratet, etc, og av ca rboxy gruppen, som alkalimetallsalter, jordalkalimetall-salter, etc.) er lett anvendbare, særlig i injeksjonspreparater. The process compounds can be used in any pharmaceutically acceptable carrier, in the form of pills, tablets or capsules. The pharmaceutically acceptable salts (both of the amino group, such as the hydrochloride, hydrobromide, sulfate, citrate, tartrate, etc., and of the ca rboxy group, such as alkali metal salts, alkaline earth metal salts, etc.) are easily usable, especially in injection preparations.
De følgende eksempler illustrerer fremstillingen av de virk-somme forbindelser. The following examples illustrate the preparation of the active compounds.
Eksempel 1 Example 1
4- aminomethylbicyclo- r2. 2. 2]- oetan- 1- carboxylsyre 4-aminomethylbicyclo-r2. 2. 2]- ethane-1- carboxylic acid
A. Hydrokloridsalt A. Hydrochloride salt
Til en oppløsning av 2,80 g (0,Ol56 mol) 4-cyanobicyclo-[2 .2.2]-octan-l-carboxylsyre (Roberts et al. JACS 1964 21, 637) i 100 ml ethanol ble tilsatt 5,0 ml 6 N saltsyre og 500 mg platinaoxyd. Under hydrogenering på et Paar-apparat ved værelsetemperatur og 2,8 kg/cm trykk, ble den teoretiske mengde hydrogen absorbert i løpet av den første halve time. Efter 2 timer ble hydrogeneringen stanset og reaksjonsblandingen filtrert gjennom sintret glass for å fjerne platinakatalysatoren. Inndampning av det klare, farveløse filtrat i vakuum (30 - 40°C) efterlot et hvitt, fast stoff som ble gjeninndampet med tre porsjoner 90%-ig ethanol for å fjerne det meste av overskuddet av saltsyre. Rensning ble utført ved oppløs-ning i 200 ml varm 95%-ig ethanol og gjenutfeining med 750 ml absolutt ethylether. Det hvite, faste stoff med smeltepunkt 318 - 319°C under spaltning (anbrakt i et forseglet kapillar ved 250°C) efter lufttørring, ble erholdt i 90,5% utbytte. Tre omkrystallisasjoner fra 95%-ig ethanol-ether ga analytisk rent materiale med smeltepunkt 318 - 319°C under spaltning, som ble tørret ved 110°C over fosforpentoxyd i 18 timer ved 0,08 mm Hg. Produktet oppviste en enkelt sirkulær ninhydrin-positiv flekk (lyserød) ved tynnskiktskromatografi på silicagel med 3:1:1 n-butanol:eddiksyre:vann, To a solution of 2.80 g (0.0156 mol) 4-cyanobicyclo-[2 .2.2]-octane-1-carboxylic acid (Roberts et al. JACS 1964 21, 637) in 100 ml of ethanol was added 5.0 ml 6 N hydrochloric acid and 500 mg platinum oxide. During hydrogenation on a Paar apparatus at room temperature and 2.8 kg/cm pressure, the theoretical amount of hydrogen was absorbed during the first half hour. After 2 hours, the hydrogenation was stopped and the reaction mixture was filtered through sintered glass to remove the platinum catalyst. Evaporation of the clear, colorless filtrate in vacuo (30-40°C) left a white solid which was re-evaporated with three portions of 90% ethanol to remove most of the excess hydrochloric acid. Purification was carried out by dissolution in 200 ml of hot 95% ethanol and re-extraction with 750 ml of absolute ethyl ether. The white solid with melting point 318 - 319°C during cleavage (placed in a sealed capillary at 250°C) after air drying, was obtained in 90.5% yield. Three recrystallizations from 95% ethanol-ether gave analytically pure material with melting point 318-319°C during cleavage, which was dried at 110°C over phosphorus pentoxide for 18 hours at 0.08 mm Hg. The product showed a single circular ninhydrin-positive spot (pink) by thin-layer chromatography on silica gel with 3:1:1 n-butanol:acetic acid:water,
Rf = 0,65. Rf = 0.65.
B. Fri aminosyre B. Free amino acid
En 300 mg prøve analytisk rent hydroklorid ble oppløst i 2 ml destillert vann, anbrakt over en kolonne av vannvasket "Dowex-1"-acetat (20 g våtvekt) og eluert med destillert vann. Prøver med ninhydrin indikerte at all fri aminosyre forelå i de første få ml elueringsmiddel. De første 100 ml elueringsmiddel ble så inndampet i vakuum (60 - 70°C), og ga den frie aminosyre. Efter 1 til 3 omkrystallisasjoner fra vann-aceton smeltet det lufttørrede materiale eller materialet tørret ved llO°C i 24 timer ved 269 - 274°C under spaltning og noen mørkning og mykning ved 265°C (anbrakt i forseglet kapillar ved l8o C), og analyse av materialet var litt lavt i carbon. Fornyet tørring ved 137°C i 24 timer'ved 0,35 mm Hg over P2°5 hevet smeltepunktet til 280 - 283°C under spaltning (mykning ved 274,5°C). A 300 mg sample of analytically pure hydrochloride was dissolved in 2 ml of distilled water, placed over a column of water-washed "Dowex-1" acetate (20 g wet weight) and eluted with distilled water. Samples with ninhydrin indicated that all free amino acid was present in the first few ml of eluent. The first 100 ml of eluent was then evaporated in vacuo (60-70°C), giving the free amino acid. After 1 to 3 recrystallizations from water-acetone, the air-dried material or the material dried at 110°C for 24 hours melted at 269 - 274°C with cleavage and some darkening and softening at 265°C (placed in sealed capillary at 180°C), and analysis of the material was slightly low in carbon. Re-drying at 137°C for 24 hours at 0.35 mm Hg above P2°5 raised the melting point to 280-283°C during cleavage (softening at 274.5°C).
Eksempel 2 Example 2
5-aminomethylbicyclo-[ 3- 2. 2]- nonan- 1- carboxylsyre- hydroklorid 5-aminomethylbicyclo-[3-2.2]-nonane-1- carboxylic acid hydrochloride
Til en oppløsning av 380 mg (1,96 mmol) 5-cyano-bicyclo-[3.2.2]-nonan-l-carboxylsyre i 40 ml absolutt ethanol ble tilsatt 20 ml destillert vann, 2,0 ml 6,0 N saltsyre og 200 mg platinaoxyd. Materialet ble hydrogenert i et Paar-apparat ved værelsetemperatur og 2,46 kg/cm i 2 timer. Efter fjernelse av katalysatoren ved filtrering ble filtratet underkastet avdrivning i vakuum ved 60 - 70°C og derpå gjeninndampet flere ganger med nye porsjoner destillert vann. Et hvitt fast stoff ble igjen som hadde smeltepunkt 286 - 289°C, i nesten kvantitativt utbytte. Tynnskiktskromatografi viste en ninhydrin positiv flekk. En omkrystallisasjon fra 95%-ig ethanol-ether ga det rene produkt med smeltepunkt 291,5 - 293°C under spaltning, i en mengde på 371 mg (8l%). Prøven ble omkrystallisert ytterligere tre ganger fra ethanol-ether for analyse, uten forandring i smeltepunkt. To a solution of 380 mg (1.96 mmol) of 5-cyano-bicyclo-[3.2.2]-nonane-1-carboxylic acid in 40 ml of absolute ethanol was added 20 ml of distilled water, 2.0 ml of 6.0 N hydrochloric acid and 200 mg platinum oxide. The material was hydrogenated in a Paar apparatus at room temperature and 2.46 kg/cm for 2 hours. After removal of the catalyst by filtration, the filtrate was subjected to stripping in vacuum at 60 - 70°C and then re-evaporated several times with new portions of distilled water. A white solid remained, mp 286-289°C, in near quantitative yield. Thin layer chromatography showed a ninhydrin positive stain. A recrystallization from 95% ethanol-ether gave the pure product with melting point 291.5 - 293°C during cleavage, in an amount of 371 mg (8l%). The sample was recrystallized a further three times from ethanol-ether for analysis, with no change in melting point.
Fremstilling av 5- cyanobicyclo- r3- 2. 2]- nonan- l- carboxylsyre Preparation of 5-cyanobicyclo-r3-2.2]-nonane-1-carboxylic acid
A. Diethyl- 6, 8- dioxobicyclo- r 3- 2. 21- nonan- l, 5- dicarboxylat A. Diethyl- 6, 8- dioxobicyclo- r 3- 2. 21- nonane- 1, 5- dicarboxylate
Til 250 ml 1,2-dimethoxyethan (friskt destillert over natriumhydrid) i en tørr atmosfære under nitrogen ble tilsatt 25,O g av en 55,7%-ig dispersjon av natriumhydrid i mineralolje (13,92 g, To 250 ml of 1,2-dimethoxyethane (freshly distilled over sodium hydride) in a dry atmosphere under nitrogen was added 25.0 g of a 55.7% dispersion of sodium hydride in mineral oil (13.92 g,
0,58 mol natriumhydrid). Til dette ble tilsatt i porsjoner i løpet av 1/2 time under mekanisk omrøring 73,8 g (0,29 mol) finpulverisert diethyl-1 ,4-cyclohexandion-2 ,5-dicarboxylat (Org. Synth. 4J5, 25 0.58 mol sodium hydride). 73.8 g (0.29 mol) finely powdered diethyl-1,4-cyclohexanedione-2,5-dicarboxylate (Org. Synth. 4J5, 25
(1966)). Hydrogen ble utviklet, blandingen ble litt varm, og en lyserød suspensjon ble dannet. Efter fjernelse av 120 ml 1,2-dimethoxyethan ved destillasjon ble der tilsatt 370 g (1,84 mol) 1,3-dibrompropan. Efter fjernelse av det meste av det gjenværende 1,2-dimethoxyethan ved destillasjon ble blandingen omrørt og oppvarmet ved 120 - 130°C i et oljebad i 65 timer. De faste stoffer ble fjernet ved filtrering, vasket med 3 x 20 ml kloroform, og for-tynnet med 400 ml hexan. Filtrering, vasking med hexan og luft-tørring ga 30,0 g (35%) krystaller med smeltepunkt 130 - 133°C (angitt: 132°C). Guha et al., Chem. Ber. 1392 (1939). Før anvendelse i det neste syntesetrinn ble materialet omkrystallisert fra 95%-ig ethanol (høyt utbytte) og ble tørret over natten ved 5o°C i vakuum og hadde da smeltepunkt 130,5 - 133°C. (1966)). Hydrogen was evolved, the mixture warmed slightly, and a pale pink suspension was formed. After removing 120 ml of 1,2-dimethoxyethane by distillation, 370 g (1.84 mol) of 1,3-dibromopropane were added. After removing most of the remaining 1,2-dimethoxyethane by distillation, the mixture was stirred and heated at 120-130°C in an oil bath for 65 hours. The solids were removed by filtration, washed with 3 x 20 ml of chloroform, and diluted with 400 ml of hexane. Filtration, washing with hexane and air-drying gave 30.0 g (35%) crystals with melting point 130 - 133°C (indicated: 132°C). Guha et al., Chem. Pray. 1392 (1939). Before use in the next synthesis step, the material was recrystallized from 95% ethanol (high yield) and was dried overnight at 5o°C in vacuum and then had a melting point of 130.5 - 133°C.
B. Diethyl-6,8-bis-ethylendithiobicyclo-[3-2.2]-nonan-l,5-dicarboxylat B. Diethyl 6,8-bis-ethylenedithiobicyclo-[3-2.2]-nonane-1,5-dicarboxylate
Til en blanding av 18,30 g (0,062 mol) finpulverisert diethyl-6,8-dioxobicyclo-[3.2.2]-nonan-l,5-dicarboxylat og 17,52 g (0,186 mol) 1,2-ethandithiol ble tilsatt 22,O g (0,155 mol) bor-trifluoridetherat. Den dannede blanding ble omrørt ved værelsetemperatur under beskyttelse mot fuktighet i 3 dager. Efter tilsetning av l6o ml kloroform ble blandingen ekstrahert med 3 x 6o ml vann, 4 x 50 ml 5%-ig natriumhydroxyd, og derpå med 3 x 6o ml vann. Efter tørring over magnesiumsulfat ga fordampning av oppløsnings-midlet en viskøs olje. Triturering med 70 ml methanol og avkjøl-ing ga 17,6 g (63,2%) av et hvitt fast stoff med smeltepunkt 101 - 103,5°C. Omkrystallisasjon fra ethanol, derpå to omkrystallisasjoner fra n-hexan ga analytisk rent materiale som nåler med smeltepunkt 103,5 - io5°c. To a mixture of 18.30 g (0.062 mol) of finely powdered diethyl-6,8-dioxobicyclo-[3.2.2]-nonane-1,5-dicarboxylate and 17.52 g (0.186 mol) of 1,2-ethanedithiol was added 22.0 g (0.155 mol) boron trifluoride etherate. The resulting mixture was stirred at room temperature under protection from moisture for 3 days. After adding 160 ml of chloroform, the mixture was extracted with 3 x 60 ml of water, 4 x 50 ml of 5% sodium hydroxide, and then with 3 x 60 ml of water. After drying over magnesium sulfate, evaporation of the solvent gave a viscous oil. Trituration with 70 ml of methanol and cooling gave 17.6 g (63.2%) of a white solid, m.p. 101 - 103.5°C. Recrystallization from ethanol, then two recrystallizations from n-hexane gave analytically pure material as needles with melting point 103.5 - 105°C.
C. Diethylbicyclo-[3.2.2]-nonan-l,5-dicarboxylat C. Diethylbicyclo-[3.2.2]-nonane-1,5-dicarboxylate
En oppløsning av 10,70 g (0,0238 mol) diethyl-6,8-bis-ethylendithio-bicyclo-[3-2.2]-nonan-l,5-dicarboxylat i 300 ml 95%-ig ethanol ble kokt under tilbakeløp med 300 g (våt vekt) aktiv Raney-nikkelkatalysator i 4 dager. Efter fjernelse av nikkelkata-lysatoren ved filtrering ble ethanolen fjernet i vakuum og produktet skilt fra tofaseblandingen med vann ved ekstraksjon i ether. De forenede etherskikt ble tørret over vannfritt magnesiumsulfat, filtrert og avdrevet, hvilket ga 5,65 g farveløs væske (88% utbytte av urent materiale). En gjentatt fremstilling ga produktet i 95% urent utbytte. A solution of 10.70 g (0.0238 mol) of diethyl-6,8-bis-ethylenedithio-bicyclo-[3-2.2]-nonane-1,5-dicarboxylate in 300 ml of 95% ethanol was refluxed with 300 g (wet weight) of active Raney nickel catalyst for 4 days. After removal of the nickel catalyst by filtration, the ethanol was removed in vacuo and the product separated from the two-phase mixture with water by extraction into ether. The combined ether layers were dried over anhydrous magnesium sulfate, filtered and stripped to give 5.65 g of colorless liquid (88% yield of impure material). A repeated preparation gave the product in 95% impure yield.
Vakuumdestillasjon av 14,5 g urent materiale ga 13,1 Q farve-løs væske med kokepunkt 142 - l45°C/0,8 mm Hg. To gjentatte destillasjoner ga en analyseprøve med kokepunkt 114 - 115°C/0,05 mm Hg. Vacuum distillation of 14.5 g of impure material gave 13.1 Q of colorless liquid with a boiling point of 142 - 145°C/0.8 mm Hg. Two repeated distillations gave an analytical sample with a boiling point of 114 - 115°C/0.05 mm Hg.
Dampfasekromatografi av dette materiale indikerte nærvær av en mindre forurensning (5% eller mindre) som ikke lot seg fjerne ved destillasjon. Materialet erholdt efter en destillasjon viste seg imidlertid å være tilstrekkelig rent for anvendelse ved fremstilling av ethyl-hydrogen-bicyclo-[3.2.2]-nonan-l,5-dicarboxylat. Vapor phase chromatography of this material indicated the presence of a minor impurity (5% or less) which could not be removed by distillation. However, the material obtained after a distillation turned out to be sufficiently pure for use in the production of ethyl hydrogen bicyclo-[3.2.2]-nonane-1,5-dicarboxylate.
D. Ethyl- hydrogen- bicyclo- f 3. 2. 2]- nonan- 1, 5- dicarboxylat D. Ethyl- hydrogen- bicyclo- f 3. 2. 2]- nonane- 1, 5- dicarboxylate
Til en oppløsning av 0,97 g (0,042 mol) rene natriumkuler i 50 ml absolutt ethanol ble tilsatt 5,0 ml destillert vann og 11,27 g To a solution of 0.97 g (0.042 mol) of pure sodium spheres in 50 ml of absolute ethanol was added 5.0 ml of distilled water and 11.27 g
(0,042 mol) diethyl-bicyclo-[3-2.2]-nonan-l,5-dicarboxylat i én porsjon. Blandingen ble omrørt magnetisk og kokt under tilbakeløp i 20 timer under nitrogen. Efter fjernelse av det meste av ethanolen i vakuum fra suspensjonen, ble 50 ml vann tilsatt til residuet. Uforsåpet diester ble fjernet ved ekstraksjon i 3 x 25 ml ether, og l,8l g (16,1%) ester ble utvunnet efter tørring og fjernelse av etheren. Syring av det avkjølte vandige skikt med 8 ml 6,0 N saltsyre ga et hvitt fast stoff som ble ekstrahert i 4 x 50 ml ethylacetat. De forenede ethylacetatskikt, ga efter tørring 7>l6 g viskøs olje. Oppløsning i 100 ml kloroform og avkjøling muliggjorde fjernelse av 0,63 g (6,5%) uønsket disyre, men adskillelsen kunne ikke utføres rent og fullstendig på denne måte som vist ved TLC-undersøkelser. Inndampning av filtratet og kromatografi over 150 g silicagel under anvendelse av kloroform som elueringsmiddel, ga monosyren mens disyren ble ikke eluert fra kolonnen. (0.042 mol) of diethyl bicyclo-[3-2.2]-nonane-1,5-dicarboxylate in one portion. The mixture was magnetically stirred and refluxed for 20 hours under nitrogen. After removing most of the ethanol in vacuo from the suspension, 50 ml of water was added to the residue. Unsaponified diester was removed by extraction in 3 x 25 ml ether, and 1.8 l g (16.1%) ester was recovered after drying and removal of the ether. Acidification of the cooled aqueous layer with 8 ml of 6.0 N hydrochloric acid gave a white solid which was extracted into 4 x 50 ml of ethyl acetate. The combined ethyl acetate layers gave, after drying, 7>16 g of viscous oil. Dissolving in 100 ml of chloroform and cooling enabled the removal of 0.63 g (6.5%) of unwanted diacid, but the separation could not be carried out cleanly and completely in this manner as shown by TLC studies. Evaporation of the filtrate and chromatography over 150 g of silica gel using chloroform as eluent gave the monoacid while the diacid was not eluted from the column.
Der ble utvunnet 6,36 g (62%) av et litt oljeaktig fast stoff som viste seg homogent ved TLC. Omkrystallisasjon fra hexan (tørris-aceton) ga materiale som smeltet ved 51 - 53,5°C. Ytterligere omkrystallisas jon av en liten mengde og til slutt sublima-sjon ga en analytisk prøve med smeltepunkt 53,5 - 55°C. There, 6.36 g (62%) of a slightly oily solid was recovered which appeared homogeneous by TLC. Recrystallization from hexane (dry ice-acetone) gave material which melted at 51 - 53.5°C. Further recrystallization of a small amount and finally sublimation gave an analytical sample with a melting point of 53.5 - 55°C.
E. Ethyl-5-carboxamidobicyclo-[3.2.2]-nonan-1-carboxylat E. Ethyl 5-carboxamidobicyclo-[3.2.2]-nonane-1-carboxylate
I en tørr nitrogenatmosfære ble 3,96 g (0,Ol65 mol) ethyl-hydrogen-bicyclo-[3•2.2]-nonan-1,5-dicarboxylat oppløst i 6o ml tørr kloroform. Efter avkjøling til -lO°C ble 1,67 g (0,0l65 mol) triethylamin tilsatt, og derpå i løpet av IO minutter 1,79 g (0,Ol65 mol) ethylklorformiat i 10 ml kloroform under omrøring, idet temperaturen ble holdt mellom -10° og -5°C. Efter omrøring i ytterligere 15 minutter ved -5°C ble ammoniakkgass boblet gjennom den omrørte blanding i 15 minutter ved stadig kjøling. Isbadet ble fjernet, og suspensjonen ble omrørt i 17 timer. Efter en omhyggelig vasking med vann, 0,5 N saltsyre, mettet natriumbicarbonat, vann og tørring over magnesiumsulfat, fjernelse av kloroformen i vakuum fikk man tilbake et hvitt fast stoff som viste seg å være homogent ved tynnskiktskromatografi, hadde smeltepunkt 8o,5 - 83°C, i et utbytte på 2,83 g (71,6%). Tre omkrystallisasjoner av en liten prøve fra benzen-hexan ga en analytisk prøve (nåler) med smeltepunkt 83,5 - 85°C. In a dry nitrogen atmosphere, 3.96 g (0.0165 mol) of ethyl hydrogen bicyclo-[3•2.2]-nonane-1,5-dicarboxylate was dissolved in 60 ml of dry chloroform. After cooling to -10°C, 1.67 g (0.0165 mol) of triethylamine was added, and then over 10 minutes 1.79 g (0.1165 mol) of ethyl chloroformate in 10 ml of chloroform while stirring, while maintaining the temperature between -10° and -5°C. After stirring for a further 15 minutes at -5°C, ammonia gas was bubbled through the stirred mixture for 15 minutes with constant cooling. The ice bath was removed and the suspension was stirred for 17 h. After careful washing with water, 0.5 N hydrochloric acid, saturated sodium bicarbonate, water and drying over magnesium sulfate, removal of the chloroform in vacuo, a white solid was recovered which proved to be homogeneous by thin layer chromatography, had a melting point of 8o.5 - 83 °C, in a yield of 2.83 g (71.6%). Three recrystallizations of a small sample from benzene-hexane gave an analytical sample (needles) with melting point 83.5 - 85°C.
F. Ethyl-5-cy anobicyclo-[ 3. 2. 2]- nonan- 1- carboxylat F. Ethyl-5-cy anobicyclo-[ 3. 2. 2]- nonane- 1- carboxylate
Til 1,44 g (6,0 mmol) ethyl-5-carboxamidobicyclo-[3.2.2]-nonan-l-carboxylat oppløst i 30 ml friskt destillert 1,2-diklorethan ble tilsatt 2,6o ml fosforoxyklorid. Blandingen ble kokt under tilbakeløp i 20 minutter med beskyttelse mot fuktighet. Efter fjernelse av det meste av overskuddet av oppløsningsmiddel og f os - foroxyklorid ved destillasjon i vakuum (6o - 70°C) ble den gjenværende røde væske behandlet med kold mettet natriumbicarbonat og produktet ekstrahert i n-pentan. Efter vasking med natriumbicarbonat og vann, og tørring over magnesiumsulfat, ga inndampning av pentanskiktet 1,13 g (86% urent) av en blek gul olje. Materialet ble vist å være homogent ved tynnskiktskromatografi, hadde de ventede absorpsjoner i infrarødt og ble forsåpet direkte til den tilsvarende cyanosyre uten ytterligere rensning. To 1.44 g (6.0 mmol) of ethyl 5-carboxamidobicyclo-[3.2.2]-nonane-1-carboxylate dissolved in 30 ml of freshly distilled 1,2-dichloroethane was added 2.60 ml of phosphorus oxychloride. The mixture was refluxed for 20 minutes with protection from moisture. After removing most of the excess solvent and phosphorus oxychloride by distillation in vacuum (6o - 70°C), the remaining red liquid was treated with cold saturated sodium bicarbonate and the product extracted into n-pentane. After washing with sodium bicarbonate and water, and drying over magnesium sulfate, evaporation of the pentane layer gave 1.13 g (86% impure) of a pale yellow oil. The material was shown to be homogeneous by thin layer chromatography, had the expected absorptions in the infrared and was saponified directly to the corresponding cyanoacid without further purification.
G. 5-cyanobicyclo-[3.2.2]-nonan-1-carboxylsyre G. 5-cyanobicyclo-[3.2.2]-nonane-1-carboxylic acid
Til 1,00 g (4,52 mmol) ethy1-5-cyanobicyclo-[3.2.2]-nonan-1-carboxylat oppløst i 20 ml absolutt ethanol ble tilsatt 2 , jO ml 2,00 N natriumhydroxyd. Blandingen ble kokt under tilbakeløp i 2 timer, og derpå omrørt over natten ved værelsetemperatur. Efter fjernelse av ethanolen i vakuum ble det gjenværende faste stoff oppløst i 20 ml vann, ekstrahert med ether, derpå syret med saltsyre og produktet ekstrahert i ether. Efter vasking og tørring over magnesiumsulfat ga fjernelse av etheren 790 mg hvitt fast stoff med smeltepunkt 184 - l88°C (87% utbytte av urent materiale). Materialet ble vist å være homogent ved tynnskiktskromatografi. Materi-alets smeltepunkt forble uforandret ved omkrystallisasjon fra benzen, og viste seg å oppfange store mengder av oppløsningsmiddel som bare ble fjernet ved tørring i vakuum ved 8o°C. En liten prøve ble omkrystallisert tre ganger fra benzen og smeltet, efter tørring for analyse, ved 186 - l88°C. To 1.00 g (4.52 mmol) of ethyl 1-5-cyanobicyclo-[3.2.2]-nonane-1-carboxylate dissolved in 20 ml of absolute ethanol was added 2.10 ml of 2.00 N sodium hydroxide. The mixture was refluxed for 2 hours, and then stirred overnight at room temperature. After removing the ethanol in vacuo, the remaining solid was dissolved in 20 ml of water, extracted with ether, then acidified with hydrochloric acid and the product extracted into ether. After washing and drying over magnesium sulfate, removal of the ether gave 790 mg of white solid with melting point 184 - 188°C (87% yield of impure material). The material was shown to be homogeneous by thin-layer chromatography. The material's melting point remained unchanged upon recrystallization from benzene, and proved to capture large amounts of solvent which was only removed by drying in vacuum at 8o°C. A small sample was recrystallized three times from benzene and melted, after drying for analysis, at 186-188°C.
Eks empe1 3 Ex empe1 3
DL- 4- aminomethylbicyclo-[2.2.2]-oeta-2,5-dion-l-carboxylsyre DL- 4-aminomethylbicyclo-[2.2.2]-oeta-2,5-dione-1-carboxylic acid
Til 590 mg (2,O mmol) 4-cyano-2,5-bis-ethylen-dioxo-bicyclo-[2.2.2]-octa-2,5-dion-l-carboxylsyre i 4o ml ethanol ble tilsatt 4,0 ml 1,0 N saltsyre og lOO mg platinaoxyd. Forbindelsen ble hydrogenert i 2 timer ved 2,11 kg/cm , filtrert og inndampet og derpå kokt under tilbakeløp i 8 timer med 20 ml 6 N saltsyre. Efter inndampning i vakuum og gjeninndarapning flere ganger med små porsjoner vann, ble det urene aminosyre-hydroklorid oppløst i 5 ml vann og ført gjennom en kolonne av 20 g "Dowex-l"-acetat. Inndampning av avløpet ga det krystallinske produkt med smeltepunkt 360°C. Flere omkrystallisasjoner fra vann-aceton ga 147 mg av aminosyren for analyse med smeltepunkt 36o°C. Materialet syntes å mørkne ved oppvarmning over 100°C og oppviste uventede infrarøde absorpsjoner 1720 cm<-1> (C=0); I6l0 cm<-1> (COOH); 1560 cm"1 (NH3+); 1450 cm"<1>; To 590 mg (2.0 mmol) of 4-cyano-2,5-bis-ethylene-dioxo-bicyclo-[2.2.2]-octa-2,5-dione-1-carboxylic acid in 40 ml of ethanol was added 4, 0 ml of 1.0 N hydrochloric acid and 100 mg of platinum oxide. The compound was hydrogenated for 2 hours at 2.11 kg/cm 2 , filtered and evaporated and then refluxed for 8 hours with 20 ml of 6 N hydrochloric acid. After evaporation in vacuo and re-evaporation several times with small portions of water, the impure amino acid hydrochloride was dissolved in 5 ml of water and passed through a column of 20 g of "Dowex-1" acetate. Evaporation of the effluent gave the crystalline product with a melting point of 360°C. Several recrystallizations from water-acetone gave 147 mg of the amino acid for analysis with a melting point of 36o°C. The material appeared to darken upon heating above 100°C and exhibited unexpected infrared absorptions 1720 cm<-1> (C=0); 16l0 cm<-1> (COOH); 1560 cm"1 (NH3+); 1450 cm"<1>;
1380 cm"<1>; 1270 cm"<1>; 1210 cm"<1>; ll40 cm"<1>; 780 cm<-1>; 560 cm"<1>; 1380cm"<1>; 1270cm"<1>; 1210 cm"<1>; ll40 cm"<1>; 780 cm<-1>; 560 cm"<1>;
350 cm"1) og syntes homogent ved tynnskiktskromatografi [R^ = 0,40 (ninhydrin) i silicagel med 3:1:1 butanol-eddiksyre-vann]. 350 cm"1) and appeared homogeneous by thin-layer chromatography [R^ = 0.40 (ninhydrin) in silica gel with 3:1:1 butanol-acetic acid-water].
Det vil sees at diket oforbindelsene fra eksempel 3 er angitt som å ha D- og L-konfigurasjon på grunn av mangel på et symmetri-plan, dvs. deres speilbilder kan ikke anbringes oppå hverandre. It will be seen that the dike junctions from Example 3 are indicated as having D and L configurations due to the lack of a plane of symmetry, ie their mirror images cannot be superimposed.
Fremstilling av DL-4-cyano-2,5-bis-(ethylendioxo)-bicyclo-[2.2.2]-octan- 1- carboxylsyre Preparation of DL-4-cyano-2,5-bis-(ethylenedioxo)-bicyclo-[2.2.2]-octane-1-carboxylic acid
A. Diethyl-2,5-bis-ethylendioxobicyclo-[2.2.2]-oetan-1,4-dicarboxylat A. Diethyl 2,5-bis-ethylenedioxobicyclo-[2.2.2]-ethane-1,4-dicarboxylate
Diethyl-2,5-bis-ethylendioxobicyclo-[2.2.2]-oetan-1,4-dicarboxylat ble fremstilt fra den tilsvarende dioxoforbindelse i det vesentlige som beskrevet av H. D. Holtz og L. M. Stock, J. Am. Chem. Soc. 86, 5183 (1964). Diethyl 2,5-bis-ethylenedioxobicyclo-[2.2.2]-ethane-1,4-dicarboxylate was prepared from the corresponding dioxo compound essentially as described by H. D. Holtz and L. M. Stock, J. Am. Chem. Soc. 86, 5183 (1964).
B. DL-et hy1-hydrogen-2,5-bis-ethylendioxobicyclo-[2.2.2]-oetan-1,4-dicarboxylat B. DL 1-hydrogen-2,5-bis-ethylenedioxobicyclo-[2.2.2]-ethane-1,4-dicarboxylate
Til en oppløsning av 58,10 g (0,157 mol) diethyl-2,5-ethylendioxobicyclo-[2.2.2]-octan-1,4-dicarboxylat i 900 ml ethanol ble tilsatt 78,5 ml 2,00 N NaOH. Blandingen ble omrørt magnetisk og kokt under tilbakeløp i 22 timer. Efter fjernelse av det meste av ethanolen i vakuum ble 250 ml vann tilsatt og blandingen ekstrahert med ethylacetat for å utvinne 20% av utgangsdiesteren som kunne resirkuleres. Det avkjølte vandige skikt ble syret med 30 ml 6 N HC1, og derpå ekstrahert flere ganger med ethylacetat. De forenede ethylacetatskikt ble vasket med vann, tørret over magnesium-sulf at , filtrert og oppløsningsmidlet avdrevet i vakuum, hvilket ga 38,4 g hvitt pulver som ved tynnskiktskromatografi ble vist å være en blanding av den ønskede monosyre med disyre ( Rf på hhv. 0,67 og 0,4l i silicagel under anvendelse av 90:25:4 benzen-dioxan-eddiksyre som elueringsmiddel). Føring av 66,5 g av dette materiale gjennom en kolonne av 500 g silicagel under anvendelse av kloroform og 9:1 kloroform-ethylacetat som elueringsmiddel muliggjorde ren adskillelse av mono- og disyren. Omkrystallisasjon av de 52,2 g uren monosyre fra kolonnen fra benzen ga det rene produkt med smeltepunkt 139 - l4l°C, i 58% utbytte beregnet på ikke-gjenvunnet disyre. Flere omkrystallisasjoner fra 95%-ig ethanol ga en analyse-prøve med smeltepunkt l4o,5 - l42°C. To a solution of 58.10 g (0.157 mol) of diethyl-2,5-ethylenedioxobicyclo-[2.2.2]-octane-1,4-dicarboxylate in 900 ml of ethanol was added 78.5 ml of 2.00 N NaOH. The mixture was magnetically stirred and refluxed for 22 h. After removing most of the ethanol in vacuo, 250 ml of water was added and the mixture was extracted with ethyl acetate to recover 20% of the starting diester which could be recycled. The cooled aqueous layer was acidified with 30 ml of 6 N HCl, and then extracted several times with ethyl acetate. The combined ethyl acetate layers were washed with water, dried over magnesium sulfate, filtered and the solvent removed in vacuo, which gave 38.4 g of white powder which, by thin-layer chromatography, was shown to be a mixture of the desired monoacid with diacid (Rf of resp. 0.67 and 0.4l in silica gel using 90:25:4 benzene-dioxane-acetic acid as eluent). Passing 66.5 g of this material through a column of 500 g of silica gel using chloroform and 9:1 chloroform-ethyl acetate as eluent allowed clean separation of the mono- and di-acids. Recrystallization of the 52.2 g of impure monoacid from the column from benzene gave the pure product with melting point 139 - 141°C, in 58% yield calculated on unrecovered diacid. Several recrystallizations from 95% ethanol yielded an analytical sample with a melting point of 140.5 - 142°C.
C. DL-ethyl-4-carboxamido-2,5-bis-ethylendioxobicyclo-[2.2.2]-octan-1- carboxylat C. DL-ethyl-4-carboxamido-2,5-bis-ethylenedioxobicyclo-[2.2.2]-octane-1-carboxylate
Til en oppløsning av 34,23 g (0,10 mol) ethyl-hydrogen-2,5-bis-ethylendioxobicyclo-[2.2.2]-octan-l,4-dicarboxylat (2) i 500 ml tørr kloroform ble tilsatt 20,24 g (0,20 mol) triethylamin. Til den omrørte, avkjølte (-10°C) oppløsning ble tilsatt 11,40 g (0,105 mol) ethylklorformiat i løpet av 30 minutter, idet temperaturen ble holdt ved -lO°C. Efter at tilsetningen var avsluttet, ble omrøringen fortsatt ved denne temperatur i ytterligere 30 minutter. Under fortsatt avkjøling i et is-saltbad ble ammoniakkgass boblet inn i blandingen i 20 - 25 minutter, og blandingen fikk lov til å oppvarmes til værelsetemperatur under omrøring over natten. Efter fjernelse av kloroformen i vakuum, tilsetning av vann og omhyggelig ekstraksjon med ethylacetat fikk man nesten analytisk rent amid (25,2 g, 74% utbytte), med smeltepunkt 159,5 - l6l,5°C. Tre omkrystallisasjoner fra 95%-ig ethanol ga en analyseprøve med smeltepunkt l6o,5 - l62°C. To a solution of 34.23 g (0.10 mol) ethyl hydrogen-2,5-bis-ethylenedioxobicyclo-[2.2.2]-octane-1,4-dicarboxylate (2) in 500 ml of dry chloroform was added 20 .24 g (0.20 mol) of triethylamine. To the stirred, cooled (-10°C) solution was added 11.40 g (0.105 mol) of ethyl chloroformate over 30 minutes, the temperature being maintained at -10°C. After the addition was complete, stirring was continued at this temperature for a further 30 minutes. With continued cooling in an ice-salt bath, ammonia gas was bubbled into the mixture for 20-25 minutes, and the mixture was allowed to warm to room temperature with stirring overnight. After removal of the chloroform in vacuo, addition of water and careful extraction with ethyl acetate, an almost analytically pure amide was obtained (25.2 g, 74% yield), with melting point 159.5 - 161.5°C. Three recrystallizations from 95% ethanol gave an analytical sample with a melting point of 160.5 - 162°C.
D. DL-ethyl-4-cyano-2,5-bis-ethylendioxobicyclo-[2.2.2]-octan-l-carboxylat D. DL-ethyl-4-cyano-2,5-bis-ethylenedioxobicyclo-[2.2.2]-octane-1-carboxylate
Til en oppløsning av 11,30 g (0,033 mol) ethyl-4-carboxamido-2,5-bis-ethylendioxobicyclo-[2.2.2]-octan-l-carboxylat i 170 ml tørr pyridin ble langsomt tilsatt 17 ml fosforoxyklorid. Den dannede oppløsning ble oppvarmet ved 70 - 8o°C i ca. 1 time. Volumet ble redusert til ca. 30 ml ved destillasjon i vakuum og det avkjølte residuum forsiktig tilsatt til ca. 300 ml mettet natriumbicarbonat inneholdende is. Ekstraksjon med ethylacetat, tørring over magnes-iumsulf at , filtrering og avdrivning av oppløsningsmidlet i vakuum ga en gul olje som størknet ved avkjøling. Omkrystallisasjon fra hexan ga rent produkt med smeltepunkt 82. - 84°C i et utbytte på To a solution of 11.30 g (0.033 mol) ethyl-4-carboxamido-2,5-bis-ethylenedioxobicyclo-[2.2.2]-octane-1-carboxylate in 170 ml of dry pyridine was slowly added 17 ml of phosphorus oxychloride. The resulting solution was heated at 70 - 8o°C for approx. 1 hour. The volume was reduced to approx. 30 ml by distillation in vacuum and the cooled residue carefully added to approx. 300 ml of saturated sodium bicarbonate containing ice. Extraction with ethyl acetate, drying over magnesium sulfate, filtration and removal of the solvent in vacuo gave a yellow oil which solidified on cooling. Recrystallization from hexane gave pure product with melting point 82. - 84°C in a yield of
9,0 g (84%). Omkrystallisasjon fra hexan ga en analyseprøve med smeltepunkt 82,5 - 84°C. 9.0 g (84%). Recrystallization from hexane gave an analytical sample with a melting point of 82.5 - 84°C.
E. DL-4-cyano-2,5-bis-ethylendioxobicyclo-[2.2.2]-octan-1- E. DL-4-cyano-2,5-bis-ethylenedioxobicyclo-[2.2.2]-octan-1-
carboxylsyre carboxylic acid
Til 2,43 g (0,075 mol) ethyl-4-cyano-2,5-bis-ethylendioxo-bicyclo-[2.2.2]-octan-l-carboxylat oppløst i 50 ml ethanol ble til- To 2.43 g (0.075 mol) ethyl 4-cyano-2,5-bis-ethylenedioxo-bicyclo-[2.2.2]-octane-1-carboxylate dissolved in 50 ml of ethanol was added
satt 8,0 ml 2,0 N natriumhydroxyd. Blandingen ble kokt under til- added 8.0 ml of 2.0 N sodium hydroxide. The mixture was boiled under
bakeløp i 6 timer under nitrogen og derpå hensatt over natten. back run for 6 hours under nitrogen and then set aside overnight.
Efter fjernelse av ethanol i vakuum og tilsetning av vann ble 0,31 9After removing the ethanol in a vacuum and adding water, 0.31 9
(12,7%) utgangsmateriale gjenvunnet ved etherekstraksjon. Forsiktig syring av det kolde vandige skikt ga en olje som hurtig begynte å (12.7%) starting material recovered by ether extraction. Careful acidification of the cold aqueous layer gave an oil which quickly began to
størkne. Produktet ble oppsamlet enten ved filtrering eller eks- solidify. The product was collected either by filtration or ex-
traksjon i ethylacetat. Efter én omkrystallisasjon av den urene cyanosyre (l,8o g, 93% beregnet på ugjenvunnet ester), fikk man 1,47 g rent produkt med smeltepunkt 223,5 - 225°C. Omkrystallisa- traction in ethyl acetate. After one recrystallization of the impure cyanoic acid (1.80 g, 93% calculated on unrecovered ester), 1.47 g of pure product with melting point 223.5 - 225°C was obtained. Recrystallize
sjon fra acetonitril ga en analyseprøve med smeltepunkt 223,5 - tion from acetonitrile gave an analytical sample with a melting point of 223.5 -
225°C. 225°C.
Claims (2)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69040467A | 1967-12-14 | 1967-12-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
NO125182B true NO125182B (en) | 1972-07-31 |
Family
ID=24772307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO4991/68A NO125182B (en) | 1967-12-14 | 1968-12-13 |
Country Status (16)
Country | Link |
---|---|
AT (1) | AT289752B (en) |
BE (1) | BE725459A (en) |
BR (1) | BR6804856D0 (en) |
CH (1) | CH518262A (en) |
DE (1) | DE1812979A1 (en) |
DK (1) | DK122809B (en) |
ES (1) | ES361113A1 (en) |
FI (1) | FI50970C (en) |
FR (2) | FR8218M (en) |
GB (1) | GB1209799A (en) |
IE (1) | IE32928B1 (en) |
IL (1) | IL31192A (en) |
NL (1) | NL6817950A (en) |
NO (1) | NO125182B (en) |
SE (1) | SE357196B (en) |
YU (2) | YU33008B (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3641128A (en) * | 1969-06-17 | 1972-02-08 | Merck & Co Inc | Antifibrinolytic compounds |
JPS4910951B1 (en) * | 1970-03-25 | 1974-03-13 | ||
IE47589B1 (en) * | 1978-01-20 | 1984-05-02 | Daiichi Seiyaku Co | Process for producing 4-amino-methylbicyclo (2,2,2)octane-1-carboxylic acid and intermediate compound therefor |
DE3336678A1 (en) * | 1983-10-08 | 1985-04-25 | Rudolf Wanzl Kg, 8874 Leipheim | Stackable shopping trolley with brake device |
DE19917999B4 (en) * | 1999-04-21 | 2007-01-11 | Brand Gülletechnik GmbH | Automatically releasing brake device for a mobile transport device |
-
1968
- 1968-12-01 IL IL31192A patent/IL31192A/en unknown
- 1968-12-02 YU YU2827/68A patent/YU33008B/en unknown
- 1968-12-02 IE IE1465/68A patent/IE32928B1/en unknown
- 1968-12-04 SE SE16572/68A patent/SE357196B/xx unknown
- 1968-12-05 ES ES361113A patent/ES361113A1/en not_active Expired
- 1968-12-05 DE DE19681812979 patent/DE1812979A1/en not_active Withdrawn
- 1968-12-09 GB GB58306/68A patent/GB1209799A/en not_active Expired
- 1968-12-09 FI FI683518A patent/FI50970C/en active
- 1968-12-13 NO NO4991/68A patent/NO125182B/no unknown
- 1968-12-13 DK DK611768AA patent/DK122809B/en not_active IP Right Cessation
- 1968-12-13 BR BR204856/68A patent/BR6804856D0/en unknown
- 1968-12-13 FR FR178115A patent/FR8218M/fr not_active Expired
- 1968-12-13 CH CH1867168A patent/CH518262A/en not_active IP Right Cessation
- 1968-12-13 BE BE725459D patent/BE725459A/xx unknown
- 1968-12-13 AT AT1216768A patent/AT289752B/en not_active IP Right Cessation
- 1968-12-13 NL NL6817950A patent/NL6817950A/xx unknown
- 1968-12-13 FR FR178116A patent/FR1605239A/fr not_active Expired
-
1973
- 1973-08-23 YU YU2271/73A patent/YU34393B/en unknown
Also Published As
Publication number | Publication date |
---|---|
NL6817950A (en) | 1969-06-17 |
FI50970C (en) | 1976-09-10 |
ES361113A1 (en) | 1970-08-01 |
YU33008B (en) | 1976-03-31 |
DE1812979A1 (en) | 1969-07-24 |
IL31192A (en) | 1972-03-28 |
FI50970B (en) | 1976-05-31 |
IL31192A0 (en) | 1969-02-27 |
IE32928B1 (en) | 1974-01-23 |
IE32928L (en) | 1969-06-14 |
GB1209799A (en) | 1970-10-21 |
YU227173A (en) | 1978-12-31 |
FR1605239A (en) | 1973-08-31 |
BE725459A (en) | 1969-06-13 |
CH518262A (en) | 1972-01-31 |
AT289752B (en) | 1971-05-10 |
DK122809B (en) | 1972-04-17 |
YU34393B (en) | 1979-07-10 |
BR6804856D0 (en) | 1973-03-20 |
SE357196B (en) | 1973-06-18 |
YU282768A (en) | 1975-08-31 |
FR8218M (en) | 1970-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI67369B (en) | FRUIT PROCESSING FOR THERAPEUTIC ACTIVATION THERAPEUTIC ACTIVE DERIVATIVES OF 3,4-DEHYDROPROLINE | |
CA2240728C (en) | Kappa agonist compounds and pharmaceutical formulations thereof | |
JPH10513438A (en) | Novel antithrombotic agent, its production method and its use | |
BG99609A (en) | New arylpropionic derivative, method for its preparation and utilization as analgesic device | |
CA2342994A1 (en) | Kappa agonist compounds and pharmaceutical formulations thereof | |
CA2953722C (en) | Crystalline (3z,5s)-5-(hydroxymethyl)-1-[(2'-methyl-1,1'-biphenyl-4-yl)carbonyl]pyrrolidin-3-one o-methyloxime, and methods of using the same | |
TWI607993B (en) | Donepezil derivative and its use | |
JP2020055825A (en) | Pharmaceutically acceptable salts of polyunsaturated hydroxy fatty acids | |
NO125182B (en) | ||
AU2008266798B2 (en) | Short acting phenylalkylamine calcium channel blockers and uses thereof | |
KR20130073945A (en) | 5α-ANDROSTANE (ALKYL)-3β,5,6β-TRIOL INJECTION AND PREPARATION METHOD THEREFOR | |
JPH0585933A (en) | Pharmaceutical for treating cataract | |
WO2022171151A1 (en) | Smtp-7 derivative and use thereof | |
JP5903166B2 (en) | Derivatives of butylphthalide and methods for producing and using the same | |
JPS5919116B2 (en) | Method for producing heterocyclic compounds | |
US3551576A (en) | Anti-fibrinolytic agent | |
NO141208B (en) | ANALOGICAL PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVITY 2- (PHENOXYALKYLTIO) IMIDAZOLE COMPOUNDS | |
US3517055A (en) | Anti-fibrinolytic agent | |
US3634499A (en) | Antifibrinolytic compounds | |
US3720775A (en) | Treatment of a pathological fibrinolytic state in patients | |
WO1999041233A1 (en) | A watersoluble nimesulide adduct also for injectable use | |
US3641128A (en) | Antifibrinolytic compounds | |
US3622610A (en) | Sulfonate esters of gallic acid derivatives | |
IE50827B1 (en) | Pyridine derivatives,process for their preparation and medicines containing them | |
CA1087193A (en) | 2- (dimethylamino)(3-pyridyl)methyl -cyclohexanol and related compounds |